NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024
26 Julio 2024 - 3:01PM
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or
the “Company”), a late-stage, clinical biopharmaceutical company
developing oral, non-statin medicines for patients at risk of
cardiovascular disease (“CVD”) with elevated low-density
lipoprotein cholesterol (“LDL-C”), for whom existing therapies are
not sufficiently effective or well-tolerated, today announced it
will report topline data from the Company’s Phase 3 BROOKLYN
clinical trial (NCT05425745) on Monday, July 29, 2024.
Conference Call and Webcast
NewAmsterdam will host a live webcast and conference call to
review the topline results from BROOKLYN on Monday, July 29th, 2024
at 8:30 a.m. ET. To access the live webcast, participants may
register here. The live webcast will be available under the
"Events” section of the Investor Relations page of the NewAmsterdam
website at ir.newamsterdampharma.com.
To participate via telephone, please register in advance here.
Upon registration, all telephone participants will receive a
confirmation email detailing how to join the conference call,
including the dial-in number along with a unique passcode and
registrant ID that can be used to access the call. While not
required, it is recommended that participants join the call ten
minutes prior to the scheduled start. An archived replay of the
webcast will be available on NewAmsterdam’s website.
About NewAmsterdam
NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage
biopharmaceutical company whose mission is to improve patient care
in populations with metabolic diseases where currently approved
therapies have not been adequate or well tolerated. We seek to fill
a significant unmet need for a safe, well-tolerated and convenient
LDL-lowering therapy. In multiple phase 3 studies, NewAmsterdam is
investigating obicetrapib, an oral, low-dose and once-daily CETP
inhibitor, alone or as a fixed-dose combination with ezetimibe, as
LDL-C lowering therapies to be used as an adjunct to statin therapy
for patients at risk of CVD with elevated LDL-C, for whom existing
therapies are not sufficiently effective or well tolerated.
Company ContactMatthew PhilippeP:
1-917-882-7512matthew.philippe@newamsterdampharma.com
Media ContactSpectrum Science on behalf of
NewAmsterdamBryan BlatsteinP:
1-917-714-2609bblatstein@spectrumscience.com
Investor ContactPrecision AQ on behalf of
NewAmsterdamAustin MurtaghP:
1-212-698-8696austin.murtagh@precisionaq.com
NewAmsterdam Pharma Comp... (NASDAQ:NAMS)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
NewAmsterdam Pharma Comp... (NASDAQ:NAMS)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024